Abstract

Neuroendocrine carcinoma breast is a distinct entity. Although clinical features and morphology cannot distinguish it from invasive carcinomas, immunochemistry plays an important role in it. Due to its rarity and lack of clinical data, treatment is followed on the lines of invasive breast carcinoma. Some studies have suggested the use of cisplatin and etoposide for its treatment, but none of them is standard. The prognosis is poor compared to invasive breast cancer.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call